Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$1.46 +2.8%	$1.25	$0.46 ▼ $7.49	$7.59M	-0.1	462,237 shs	80,710 shs
FRX Forest Road Acquisition		$10.30	$9.72 ▼ $18.20	$450M	N/A	2.07 million shs	40,482 shs
IPA ImmunoPrecise Antibodies	$2.02 +1.5%	$1.47	$0.27 ▼ $2.41	$91.85M	0.49	1.35 million shs	450,871 shs
WMD WeedMD	C$0.28 -1.8%	C$0.28	C$0.23 ▼ C$0.99	C$67.82M	N/A	766,591 shs	271,436 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	+2.82%	+13.18%	+50.55%	+53.35%	-55.49%
FRX Forest Road Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
IPA ImmunoPrecise Antibodies	+1.51%	+9.19%	+10.99%	+308.25%	+197.06%
WMD WeedMD	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APM Aptorum Group	0.8272 of 5 stars	0.0	2.0	0.0	0.0	3.0	1.7	0.6
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	2.2809 of 5 stars	3.5	3.0	0.0	0.0	2.5	0.0	0.6
WMD WeedMD	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	0.00	N/A	N/A	N/A
FRX Forest Road Acquisition	0.00	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	98.02% Upside
WMD WeedMD	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	18.17	N/A	N/A	$2.20 per share	0.66
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	$0.56 per share	N/A
IPA ImmunoPrecise Antibodies	$17.59M	5.30	N/A	N/A	$0.37 per share	5.46
WMD WeedMD	C$27.53M	2.46	C$0.08 per share	3.27	C$0.34 per share	0.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$4.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
FRX Forest Road Acquisition	-$7.92M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	-$21.69M	-$0.68	N/A	N/A	N/A	-122.10%	-40.62%	-22.19%	9/15/2025 (Estimated)
WMD WeedMD	N/A	-C$0.42	N/A	∞	N/A	N/A	N/A	N/A	N/A

Latest WMD, FRX, IPA, and APM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/29/2025	Q4 2025	IPA ImmunoPrecise Antibodies	-$0.02	-$0.04	-$0.02	-$0.04	$7.89 million	$5.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
WMD WeedMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.22	0.22
FRX Forest Road Acquisition	N/A	0.37	0.37
IPA ImmunoPrecise Antibodies	0.49	2.08	1.85
WMD WeedMD	95.63	3.46	1.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
FRX Forest Road Acquisition	N/A
IPA ImmunoPrecise Antibodies	6.70%
WMD WeedMD	N/A

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
FRX Forest Road Acquisition	N/A
IPA ImmunoPrecise Antibodies	6.83%
WMD WeedMD	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	5.35 million	1.93 million	Not Optionable
FRX Forest Road Acquisition	N/A	37.50 million	N/A	Not Optionable
IPA ImmunoPrecise Antibodies	80	46.15 million	43.00 million	Not Optionable
WMD WeedMD	628	246.62 million	N/A	Not Optionable

WMD, FRX, IPA, and APM Headlines

Recent News About These Companies

ENTG:CA Entourage Health Corp.

October 19, 2024 | seekingalpha.com

Hurricane Helene by the numbers: Catastrophic destruction covers 400 miles

October 4, 2024 | abcnews.go.com

WMDH WMD Holdings Group, Inc.

September 27, 2024 | seekingalpha.com

Ethics and Weapons of Mass Destruction

August 8, 2024 | cambridge.orgC

'Truth about WMD will finally emerge'

March 4, 2024 | dailymail.co.uk

No cabinet submission on costs, benefits, implications of going to war in Iraq

January 3, 2024 | theaustralian.com.au

Blair: 'Saddam still has weapons of mass destruction'

October 4, 2023 | dailymail.co.uk

Bush administration retreats on WMD claim

August 29, 2023 | namibian.com.naN

Missing WMD ‘hurting war on terror’

August 29, 2023 | namibian.com.naN

Weapons of Mass Destruction and the ethics of their usage

August 17, 2023 | arstechnica.comA

Russia used sabotaged dam as ‘weapon of mass destruction’ says Ukraine

June 12, 2023 | politico.euP

US, South Korea issue fresh North Korea sanctions on 'illicit' IT workforce

May 27, 2023 | asahi.comA

Malaysia Gets Tough on WMD

May 27, 2023 | thediplomat.comT

Interpol Tackles WMD Terrorism

May 21, 2023 | thediplomat.comT

'Weapons of mass destruction found'

May 20, 2023 | dailymail.co.uk

Chemical Weapons are NOT WMDs

May 17, 2023 | thediplomat.comT

The Next Financial WMD?

May 14, 2023 | thestreet.com

The Week in Weed – May 6, 2023 - StratCann

May 6, 2023 | news.google.comN

WMD in Iraq: Evidence and Implications

April 28, 2023 | medscape.comM

What happened when WMD experts tried to make the GPT-4 AI do bad things

April 1, 2023 | thebulletin.orgT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

WMD, FRX, IPA, and APM Company Descriptions

Aptorum Group NASDAQ:APM

$1.46 +0.04 (+2.82%)

Closing price 08/14/2025 03:57 PM Eastern

Extended Trading

$1.44 -0.02 (-1.71%)

As of 08/14/2025 07:55 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Forest Road Acquisition NYSE:FRX

Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.

ImmunoPrecise Antibodies NASDAQ:IPA

$2.02 +0.03 (+1.51%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.98 -0.04 (-1.98%)

As of 08/14/2025 07:46 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

WeedMD CVE:WMD

C$0.28 -0.01 (-1.79%)

As of 07/15/2021

WeedMD Inc. produces, distributes, and sells medical-grade cannabis in Canada. It offers dried cannabis, cannabis plants and seeds, cannabis oil, edibles, extracts and topicals, and others, as well as cannabis flower products. The company sells its products directly to medical patients and strategic relationships across the seniors' market, as well as through supply agreements with Shoppers Drug Mart and six provincial distribution agencies under the Color Cannabis, Saturday, Starseed, and WeedMD brand names. WeedMD Inc. is headquartered in Aylmer, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time